Abstract

Chewy, Inc. will report fiscal second-quarter 2026 results on September 9, 2026, Pre-MKt; this preview compiles the latest financial estimates, last-quarter performance, business segment updates, and prevailing analyst expectations to frame the likely earnings trajectory and the stock’s near-term drivers.

Market Forecast

Consensus models point to fiscal Q2 revenue of 3.32 billion US dollars, an increase of 7.77% year over year, with adjusted EPS estimated at 0.18, up 26.64% year over year; EBIT is projected at 108.61 million US dollars, indicating 47.95% year-over-year growth. Revenue mix remains anchored by the core retail categories, with management and external previews broadly anticipating a steady operating cadence into the print. The company’s core retail categories are expected to continue providing scale and recurring order stability, while healthcare-adjacent offerings deepen engagement. The most promising revenue contributor for expansion remains Pet Health and Specialty Products, which delivered 562.70 million US dollars last quarter and continues to benefit from higher-value purchase patterns and ecosystem tie-ins.

Last Quarter Review

In fiscal Q1 2026, Chewy, Inc. reported revenue of 3.36 billion US dollars (up 7.74% year over year), a gross profit margin of 30.13%, GAAP net profit attributable to the company of 94.80 million US dollars and a net profit margin of 2.82%; adjusted EPS was 0.23, growing 43.75% year over year. A key financial takeaway was the maintenance of roughly 30% gross margin alongside year-over-year growth in adjusted EPS and sustained profitability, reflecting operating discipline. By business line, last quarter saw 2.29 billion US dollars from Consumables, 562.70 million US dollars from Pet Health and Specialty Products, 394.80 million US dollars from Hardgoods, and 107.30 million US dollars from Other; segment-level year-over-year changes were not disclosed.

Current Quarter Outlook

Main Business: Core Retail and Autoship Engine

The central focus this quarter is the balance between growth and profitability in the core retail engine. After achieving 3.36 billion US dollars last quarter with a 30.13% gross profit margin, the company enters fiscal Q2 with consensus revenue models at 3.32 billion US dollars and adjusted EPS around 0.18, reflecting expectations for disciplined execution while navigating a more selective consumer. Analyst previews indicate a modest deceleration from the prior quarter’s revenue base, consistent with a category backdrop that has remained muted, yet they continue to point to incremental market share gains and broad operating stability. Engagement metrics are in the spotlight, especially active customer counts and order frequency, because they can offset softer discretionary demand through recurring buying patterns and replenishment orders. One widely cited preview anticipates approximately 21.67 million active customers for the quarter, a level that, if reached, would indicate healthy net additions even as the category remains measured. The interplay of promotions and margin preservation is another clear watchpoint: external commentary suggests the company has prioritized profitability by trimming lower-return discounting, which could support steady gross margin while potentially tempering top-line velocity in the near term. Freight, fulfillment, and last-mile costs can influence reported margin variability intra-quarter, and the company’s ability to manage these inputs remains an important lever for earnings translation. Mix also matters: the consumables-heavy basket stabilizes revenue but typically carries lower margins than certain health-adjacent categories, so any shift toward higher-value cross-sell can aid overall profitability. Into the print, the prevailing expectation is that the business will demonstrate enough efficiency to keep margins broadly aligned with recent trends while sustaining mid-to-high single-digit top-line growth versus the prior year. Management updates around customer growth, order frequency, and revenue-per-active customer will be key markers for how the model balances scale and margin over the balance of the fiscal year.

Most Promising Business: Pet Health and Veterinary Ecosystem Expansion

Pet Health and Specialty Products continues to stand out as the largest near-term expansion opportunity within the company’s mix. It contributed 562.70 million US dollars last quarter, and external previews suggest investors are focused on how health-adjacent offerings can enhance average order value, deepen customer relationships, and create a path to higher lifetime value. The recently announced plan to acquire Modern Animal, alongside the board’s approval of a 500 million US dollars increase to the share repurchase program, underscores management’s commitment to enhancing shareholder value while broadening the healthcare ecosystem. Notably, the acquisition is expected to be EBITDA dollar-neutral in fiscal 2026 on a pro forma basis and accretive to EPS within the first year following close, based on the company’s indication. Beyond direct revenue, the healthcare ecosystem can shape customer behavior by adding convenience, service integration, and trust factors that encourage retention. In investor previews, this segment is often highlighted for its potential to raise wallet share as customers engage with services beyond traditional retail purchases. As fiscal Q2 results approach, commentary about clinic rollout pacing, service attach rates, and cross-sell to product categories will be dissected for their early indicators of scale and margin uplift. The degree to which these initiatives offset category-level caution in discretionary items will also inform the durability of consolidated growth in the back half of the fiscal year.

What Will Move the Stock: Guidance, Customer Trajectory, and Margins

Three variables are positioned to drive the stock’s reaction on the print: guidance, active customer trajectory, and the margin framework. On guidance, external previews argue that reaffirmation of the fiscal 2026 revenue growth outlook in the 6.5%–7.5% range would be read constructively, especially if framed with commentary about market share continuity and operational levers that support profitability. If management provides additional color on the revenue cadence for the second half and confirms confidence in its cost structure, the market is likely to treat that as a signal of steady execution despite a measured category backdrop. Active customers remain a linchpin stock driver because they seed future sales through replenishment and ongoing purchase behaviors. Expectations cited by one major institution suggest around 21.67 million active customers for the quarter, and results above or below this marker can influence how investors extrapolate full-year revenue and customer value. At the same time, margin quality and mix will be scrutinized: indications that gross margin can hold near the recent 30% level while net margin benefits from operating leverage would strengthen the case for earnings consistency. Conversely, any sign that higher promotions or fulfillment cost inflation is pressuring the margin narrative could dampen enthusiasm even if absolute revenue tracks near consensus. Additionally, capital allocation will feature in the market’s interpretation of the print. The expanded repurchase authorization provides flexibility to return capital while signaling longer-term confidence, which can mitigate volatility if near-term top-line growth remains bounded by consumer selectivity. Progress updates on the healthcare ecosystem—particularly around the planned Modern Animal acquisition timeline, integration plans, and the expected financial profile—will feed into how investors handicap the mix shift toward higher-value offerings. Clarity on these drivers, combined with customer count and revenue cadence, should largely determine whether shares gravitate toward the high end of near-term fair-value ranges post-earnings.

Analyst Opinions

Across the latest six months of commentary, the balance of views is bullish, with favorable ratings outnumbering neutral/guarded stances. By institution count, bullish opinions hold a slight majority over neutral/bearish takes (approximately four supportive institutions versus three neutral stances), and the discussion below reflects that dominant view. RBC Capital Markets maintains a supportive stance into the quarter and expects the company to “demonstrate consistent market share gains and reaffirm its full-year guidance” during the fiscal Q2 release. One of the bank’s previews also frames quarterly net sales growth at roughly 6.8%, close to broad sell-side models, while flagging about 21.67 million active customers as a reasonable bar for engagement. In the same preview cycle, RBC kept its outperform rating and cited a 34.00 US dollars price target, signaling confidence that steady execution can coexist with a muted category. William Blair has reiterated its Buy rating, emphasizing that recent results and prudently calibrated outlook commentary have reinforced earnings confidence. Analysts there have pointed to the company’s ability to compound operational improvements even as it carefully adjusts growth priorities to protect margin. Their stance is that tactically balanced cost and growth management, coupled with durable engagement, can sustain the earnings trajectory through the year. TD Cowen has reaffirmed a Buy view ahead of earlier milestones this fiscal year, expecting solid delivery against guidance. The firm’s framing suggests that scale, customer engagement, and the efficiency toolkit remain intact, supporting a path to meet or slightly exceed internal pacing. While demand normalization and consumer selectivity are acknowledged, TD Cowen continues to highlight the company’s levers to sustain growth and margin balance. Piper Sandler remains constructive with an Overweight rating, while acknowledging that forward sales growth expectations have moderated as consumers become more selective. Even after trimming its price target to 30.00 US dollars during the mid-year recalibration, Piper’s stance stays aligned with the supportive consensus and keeps the focus on execution quality and the potential for margin steadiness. The firm’s call effectively argues that a disciplined approach to promotions and investments should preserve earnings resilience even if top-line accelerants are limited in the near term. The bullish camp’s core argument rests on four planks: steady market share gains despite a measured demand environment; disciplined margin stewardship that has kept gross margin near 30%; a consistent engagement engine that supports revenue visibility; and a clearly articulated healthcare ecosystem roadmap with targeted capital allocation, including the planned Modern Animal acquisition and an expanded repurchase authorization. These elements combine to support consensus expectations of 3.32 billion US dollars revenue and 0.18 adjusted EPS for fiscal Q2, with upside potential skewed toward execution on active customer additions and stable margins. Taken together, the majority view anticipates a print that validates the current run-rate—mid-to-high single-digit year-over-year revenue growth with durable profitability signals—and a management message that reaffirms full-year guardrails. If those expectations are met, bulls believe the setup can help narrow the valuation debate that has oscillated alongside category headlines this year. The read-through for the stock, in the bullish framing, hinges primarily on guidance tone, customer metrics, and confirmation that the healthcare ecosystem is tracking to plan, leaving the company positioned to compound earnings quality into the back half of the fiscal year.